Synergy and Duality in Peptide Antibiotic Mechanisms Dewey G Mccafferty*, Predrag Cudic, Michael K Yu, Douglas C Behenna and Ryan Kruger

Total Page:16

File Type:pdf, Size:1020Kb

Synergy and Duality in Peptide Antibiotic Mechanisms Dewey G Mccafferty*, Predrag Cudic, Michael K Yu, Douglas C Behenna and Ryan Kruger ch3616.qxd 11/24/1999 9:55 AM Page 672 672 Synergy and duality in peptide antibiotic mechanisms Dewey G McCafferty*, Predrag Cudic, Michael K Yu, Douglas C Behenna and Ryan Kruger The molecular mechanisms by which peptide antibiotics Synergistic peptide antibiotics disrupt bacterial DNA synthesis, protein biosynthesis, cell wall Synergism in targeting ribosomal protein biosynthesis biosynthesis, and membrane integrity are diverse, yet Thiopeptide antibiotics historically have been understood to follow a theme of one Thiostrepton and micrococcin are members of the class of antibiotic, one inhibitory mechanism. In the past year, thiazole-containing peptide antibiotics (or thiopeptide mechanistic and structural studies have shown a rich diversity antibiotics), which inhibit protein biosynthesis by binding in peptide antibiotic mechanism. Novel secondary targeting to the 23S rRNA subunit of the ribosome and preventing mechanisms for peptide antibiotics have recently been its proper function [1•–3•]. This family of antibiotics (see discovered, and the mechanisms of peptide antibiotics Figure 1) is characterized by highly modified peptide involved in synergistic relationships with antibiotics and backbones, in which thiazole, 4,2′-bisthiazole, didehy- proteins have been more clearly defined. In apparent response droalanine and didehydrobutyrine residues are formed to selective pressures, antibiotic-producing organisms have from oxidative cyclization and dehydration modifications elegantly integrated multiple functions and cooperative of cysteine, serine and threonine residues [4•]. interactions into peptide antibiotic design for the purpose of improving antimicrobial success. The 23S rRNA site where GTPase-driven elongation fac- tors EF-Tu and EF-G bind is one of the most important functional regions of the ribosome. This site is character- Addresses Department of Biochemistry and Biophysics and Johnson Research ized by two highly conserved regions of the 23S rRNA Foundation, The University of Pennsylvania School of Medicine, ribosomal subunit, the 17-nucleotide sarcin/ricin loop, and Philadelphia, PA 19104-6059, USA the 58-nucleotide domain associated with the ribosomal *e-mail: [email protected] protein L11. Binding of the L11 carboxyl terminus to the Current Opinion in Chemical Biology 1999, 3:672–680 58-nucleotide domain of the rRNA stabilizes its folded con- formation [5••,6••]. The amino-terminal domain of L11 is 1367-5931/99/$ — see front matter © 1999 Elsevier Science Ltd. highly conserved, proline-rich, and functions as a molecular All rights reserved. switch, mediating a conformational change that allows elon- Abbreviations gation factors to properly bind and propagate peptide EF elongation factor synthesis. Thiopeptide antibiotics bind to the 23S rRNA Lipid I undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide and place a conformational constraint on protein L11, lock- Lipid II undecaprenyl-pyrophosphoryl-MurNAc-(GlcNAc)- ing it into a conformation that disfavors proper binding pentapeptide PBP penicillin-binding protein and/or function of EF-Tu and EF-G, effectively halting PE phosphatidylethanolamine protein synthesis [1•,2•]. Remarkably, thiostrepton-producing microorganisms have tailored this antibiotic not only to target a unique, function- Introduction ally-important conformational change in protein L11 but Peptide antibiotics are produced by bacterial, mam- also to manipulate this essential protein for the purpose of malian, insect, and plant organisms in defense against conferring cooperative, high-affinity binding and intimate invasive microbial pathogens. Evolution has crafted pep- specificity. Binding of thiostrepton and L11 protein togeth- tide antibiotics into functionally optimized compounds er to rRNA is synergistic and cooperative and essentially with defined specificity and higher order functionality. irreversible [7]; however, in the absence of rRNA, thiostrep- The number and composition of peptide antibiotics are ton and L11 do not associate and without L11 thiostrepton myriad, reflecting origins from ribosomal, post-transla- affinity for rRNA is comparatively weak [6••]. tional, or non-ribosomal biosynthetic means. Likewise their modes of action are equally diverse. As our under- The molecular basis for this unusual synergistic relation- standing of peptide antibiotic mechanisms steadily ship is rapidly becoming clearer. Resistant mutants and increases, two prevalent mechanistic themes are emerg- chemical footprinting experiments have been employed to ing: molecular synergy and functional duality. Molecular predict the target sites of thiostrepton and micrococcin. synergy is defined as the combined action of two or more High level resistance to thiostrepton is conferred both by antibiotics toward a single target molecule. Functional mutation of the conserved amino-terminal helix of L11 at duality is defined as one molecule having dual antibiotic Pro22, as well as by rRNA 2′-O-methylation at A1067 and activity. The purpose of this review is to survey recent mutation of nucleotides A1067 and A1095. Footprinting examples of the intriguing themes of synergy and duali- experiments confirmed protection of these nucleotide posi- ty in peptide antibiotic mechanism. tions with thiostrepton and micrococcin, suggesting that ch3616.qxd 11/24/1999 9:55 AM Page 673 Synergy and duality in peptide antibiotic mechanisms McCafferty et al. 673 Figure 1 Chemical structures of synergistic ribosome- targeting peptide antibiotics. N O O N OH N N H O HN R O O O 1 O O N O H O N O N O N O NH O O HO N Pristinamycin IIA Pristinamycin IA OH ONH2 ONH HN HN O O O S N N S H O N N S N H O S N H N N N S N N O H HO S HN O H N O N N O HO S HN HN O HO S HN O O O N HN HN OH H O S N N O S H N N O OH N HO S O Micrococcin Thiostrepton Current Opinion in Chemical Biology the two antibiotics bind to overlapping regions of rRNA. peptide-derived antibiotics that act synergistically to White and co-workers [6••] recently reported the crystal inhibit ribosomal peptidyl transfer during bacterial protein structure of the L11–rRNA complex, which confirmed the biosynthesis [8–10]. Streptogramin type A (pristi- hypothesis that A1067, A1089 of the rRNA and the amino- namycin IIA, virginiamycin M1) and type B terminal proline-rich helix of L11 are adjacent and suggests (pristinamycin IA, virginiamycin S1) antibiotics are macro- that the exposed cleft between the three juxtaposed cyclic lactone peptolides produced by Streptomyces strands is the candidate thiostrepton-binding site pristinaespiralis and Streptomyces virginiae. Type A strep- (Figure 2). From the structure of the L11–rRNA complex, togramins inactivate the donor (P) and acceptor (A) sites of synergistic binding could be explained by initial displace- the peptidyl transferase region of the 23S rRNA subunit by ment of a loosely-associated amino-terminal helix of L11 by blocking two of the peptide chain elongation steps: thiostrepton followed by back-binding of the displaced aminoacyl–tRNA binding to the A site; and peptide bond helix onto the rRNA–antibiotic complex, locking in the formation with peptidyl–tRNA at the P site. The type B tightly-associated ternary complex. Thiopeptides also con- streptogramins inhibit peptide bond formation by binding tain potentially reactive didehydroalanine residues, which to the 23S rRNA peptidyl transferase loop, forcing the could participate in covalent capture of either rRNA or L11. release of incomplete peptide chains [9,10]. This mode of Confirmation of structure of the ternary complex by X-ray action is similar to that of the 14-member macrolide fami- analysis is anxiously awaited and will, we hope, better our ly of antibiotics (which includes erythromycin) and also to understanding of the molecular basis of the observed syn- that of the lincosamides, and suggests that streptogramin B ergy and high affinity association. antibiotics share overlapping binding sites with these structurally unrelated antibiotics [9]. Streptogramin antibiotics The streptogramin antibiotics (also known as the syn- Separately, streptogramins A and B are bacteriostatic, yet ergimycins) consist of pairs of structurally unrelated when administered in combination in vivo the antibiotics ch3616.qxd 11/24/1999 9:55 AM Page 674 674 Biopolymers Figure 2 same RNA binding site (as shown by their overlapping footprints), suggesting that a unique heterodimeric antibi- otic complex forms upon contact with RNA that juxtaposes regions 2058–2062 with 2503–2506, simultaneously bridg- Thiostrepton binding site ing the two adjacent strands of the 23S rRNA. A1067 Synergism in membrane permeabilization A1095 As a defense mechanism against microbial pathogens, insects, mammals, amphibians, and plants produce antimi- crobial polypeptides such as the defensins, cecropins, magainins, and the type A lantibiotics [14•–16•,17,18•,19•]. Antimicrobial peptides in these classes are produced riboso- mally, and in some cases undergo further post-translational Pro22 modifications that are essential for export and optimal activ- ity. Typically cationic, peptides in these classes generally act by interacting with anionic membrane phospholipids caus- ing pore formation, which leads to disruption of the proton motive force, cell metabolite leakage, and cellular lysis. Within these classes (Table 1) a common theme of func- tional synergism between membrane targeting peptide antibiotics is rapidly emerging. Current Opinion in Chemical Biology Magainins Magainin 2 and PGLa are members of the magainin fami-
Recommended publications
  • National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): a Cross-Sectional Study
    Tropical Medicine and Infectious Disease Article National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): A Cross-Sectional Study Joseph Sam Kanu 1,2,* , Mohammed Khogali 3, Katrina Hann 4 , Wenjing Tao 5, Shuwary Barlatt 6,7, James Komeh 6, Joy Johnson 6, Mohamed Sesay 6, Mohamed Alex Vandi 8, Hannock Tweya 9, Collins Timire 10, Onome Thomas Abiri 6,11 , Fawzi Thomas 6, Ahmed Sankoh-Hughes 12, Bailah Molleh 4, Anna Maruta 13 and Anthony D. Harries 10,14 1 National Disease Surveillance Programme, Sierra Leone National Public Health Emergency Operations Centre, Ministry of Health and Sanitation, Cockerill, Wilkinson Road, Freetown, Sierra Leone 2 Department of Community Health, Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone 3 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva, Switzerland; [email protected] 4 Sustainable Health Systems, Freetown, Sierra Leone; [email protected] (K.H.); [email protected] (B.M.) 5 Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, Folkhalsomyndigheten, SE-171 82 Stockholm, Sweden; [email protected] 6 Pharmacy Board of Sierra Leone, Central Medical Stores, New England Ville, Freetown, Sierra Leone; [email protected] (S.B.); [email protected] (J.K.); [email protected] (J.J.); [email protected] (M.S.); [email protected] (O.T.A.); [email protected] (F.T.) Citation: Kanu, J.S.; Khogali, M.; 7 Department of Pharmaceutics and Clinical Pharmacy & Therapeutics, Faculty of Pharmaceutical Sciences, Hann, K.; Tao, W.; Barlatt, S.; Komeh, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown 0000, Sierra Leone 8 J.; Johnson, J.; Sesay, M.; Vandi, M.A.; Directorate of Health Security & Emergencies, Ministry of Health and Sanitation, Sierra Leone National Tweya, H.; et al.
    [Show full text]
  • Novel Antimicrobial Agents Inhibiting Lipid II Incorporation Into Peptidoglycan Essay MBB
    27 -7-2019 Novel antimicrobial agents inhibiting lipid II incorporation into peptidoglycan Essay MBB Mark Nijland S3265978 Supervisor: Prof. Dr. Dirk-Jan Scheffers Molecular Microbiology University of Groningen Content Abstract..............................................................................................................................................2 1.0 Peptidoglycan biosynthesis of bacteria ........................................................................................3 2.0 Novel antimicrobial agents ...........................................................................................................4 2.1 Teixobactin ...............................................................................................................................4 2.2 tridecaptin A1............................................................................................................................7 2.3 Malacidins ................................................................................................................................8 2.4 Humimycins ..............................................................................................................................9 2.5 LysM ........................................................................................................................................ 10 3.0 Concluding remarks .................................................................................................................... 11 4.0 references .................................................................................................................................
    [Show full text]
  • Brilacidin First-In-Class Defensin-Mimetic Drug Candidate
    Brilacidin First-in-Class Defensin-Mimetic Drug Candidate Mechanism of Action, Pre/Clinical Data and Academic Literature Supporting the Development of Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment April 20, 2020 Page # I. Brilacidin: Background Information 2 II. Brilacidin: Two Primary Mechanisms of Action 3 Membrane Disruption 4 Immunomodulatory 7 III. Brilacidin: Several Complementary Ways of Targeting COVID-19 10 Antiviral (anti-SARS-CoV-2 activity) 11 Immuno/Anti-Inflammatory 13 Antimicrobial 16 IV. Brilacidin: COVID-19 Clinical Development Pathways 18 Drug 18 Vaccine 20 Next Steps 24 V. Brilacidin: Phase 2 Clinical Trial Data in Other Indications 25 VI. AMPs/Defensins (Mimetics): Antiviral Properties 30 VII. AMPs/Defensins (Mimetics): Anti-Coronavirus Potential 33 VIII. The Broader Context: Characteristics of the COVID-19 Pandemic 36 Innovation Pharmaceuticals 301 Edgewater Place, Ste 100 Wakefield, MA 01880 978.921.4125 [email protected] Innovation Pharmaceuticals: Mechanism of Action, Pre/Clinical Data and Academic Literature Supporting the Development of Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment (April 20, 2020) Page 1 of 45 I. Brilacidin: Background Information Brilacidin (PMX-30063) is Innovation Pharmaceutical’s lead Host Defense Protein (HDP)/Defensin-Mimetic drug candidate targeting SARS-CoV-2, the virus responsible for COVID-19. Laboratory testing conducted at a U.S.-based Regional Biocontainment Laboratory (RBL) supports Brilacidin’s antiviral activity in directly inhibiting SARS-CoV-2 in cell-based assays. Additional pre-clinical and clinical data support Brilacidin’s therapeutic potential to inhibit the production of IL-6, IL-1, TNF- and other pro-inflammatory cytokines and chemokines (e.g., MCP-1), identified as central drivers in the worsening prognoses of COVID-19 patients.
    [Show full text]
  • Penicillin Allergy Guidance Document
    Penicillin Allergy Guidance Document Key Points Background Careful evaluation of antibiotic allergy and prior tolerance history is essential to providing optimal treatment The true incidence of penicillin hypersensitivity amongst patients in the United States is less than 1% Alterations in antibiotic prescribing due to reported penicillin allergy has been shown to result in higher costs, increased risk of antibiotic resistance, and worse patient outcomes Cross-reactivity between truly penicillin allergic patients and later generation cephalosporins and/or carbapenems is rare Evaluation of Penicillin Allergy Obtain a detailed history of allergic reaction Classify the type and severity of the reaction paying particular attention to any IgE-mediated reactions (e.g., anaphylaxis, hives, angioedema, etc.) (Table 1) Evaluate prior tolerance of beta-lactam antibiotics utilizing patient interview or the electronic medical record Recommendations for Challenging Penicillin Allergic Patients See Figure 1 Follow-Up Document tolerance or intolerance in the patient’s allergy history Consider referring to allergy clinic for skin testing Created July 2017 by Macey Wolfe, PharmD; John Schoen, PharmD, BCPS; Scott Bergman, PharmD, BCPS; Sara May, MD; and Trevor Van Schooneveld, MD, FACP Disclaimer: This resource is intended for non-commercial educational and quality improvement purposes. Outside entities may utilize for these purposes, but must acknowledge the source. The guidance is intended to assist practitioners in managing a clinical situation but is not mandatory. The interprofessional group of authors have made considerable efforts to ensure the information upon which they are based is accurate and up to date. Any treatments have some inherent risk. Recommendations are meant to improve quality of patient care yet should not replace clinical judgment.
    [Show full text]
  • Antibiotic Resistance: Nosopharm and the University of Illinois at Chicago Describe Mechanism of Action of New Class of Antibiotics in Molecular Cell
    Antibiotic resistance: Nosopharm and the University of Illinois at Chicago describe mechanism of action of new class of antibiotics in Molecular Cell Newly discovered antibiotic binds to ribosome and disrupts protein synthesis Lyon, France, and Chicago (IL), United States - April 5 2018 – Nosopharm, a company dedicated to the research and development of new anti-infective drugs, and the University of Illinois at Chicago (UIC) today announce the publication of a study in Molecular Cell on the mechanism of action of odilorhabdins, a new class of antibiotics to combat antibiotic resistance. The antibiotic, first identified by Nosopharm, is unique and promising on two fronts: its unconventional source and its distinct way of killing bacteria, both of which suggest the compound may be effective at treating drug-resistant or hard to treat bacterial infections. Called odilorhabdins, or ODLs, the antibiotics are produced by symbiotic bacteria found in soil-dwelling nematode worms that colonize insects for food. The bacteria help to kill the insect and, importantly, secrete the antibiotic to keep competing bacteria away. Until now, these nematode-associated bacteria and the antibiotics they make have been largely understudied. The odilorhabdin program was launched by Nosopharm in 2011. To identify the antibiotic, Nosopharm’s researchers team screened eighty cultured strains of the bacteria for antimicrobial activity. They then isolated the active compounds, studied their chemical structures and their structure-activity relationships, investigated their pharmacology and engineered more potent derivatives. The study, published in Molecular Cell1, describes the new antibiotic and, for the first time, how it works. Nosopharm’s Maxime Gualtieri, UIC's Alexander Mankin and Yury Polikanov are corresponding authors on the study and led the research on the antibiotic's mechanism of action.
    [Show full text]
  • Polymyxin B* Class: Polymyxins Overview Polymyxin B Is a Polypeptide Bactericidal Antibiotic. the Polymyxins Were Discovered In
    Polymyxin B* Class: Polymyxins Overview Polymyxin B is a polypeptide bactericidal antibiotic. The polymyxins were discovered in 1947 and introduced to the medical community in the 1950s. Colistin, also called polymyxin E and its parenteral form, colistimethate, are related polymyxins. Polymyxins can be administered orally, topically or parenterally, including intrathecally and intraperitoneally. However parenteral administration is primarily used in life threatening infections caused by Gram-negative bacilli or Pseudomonas species that are resistant to other drugs. Polymyxins exert their effect on the bacterial cell membrane by affecting phospholipids and interfering with membrane function and permeability, which results in cell death. Polymyxins are more effective against Gram-negative than Gram- positive bacteria and are effective against all Gram-negative bacteria except Proteus species. These antibiotics act synergistically with potentiated sulfonamides, tetracyclines and certain other antimicrobials. Polymyxins also limit activity of endotoxins in body fluids and therefore, may be beneficial in therapy for endotoxemia. Polymyxins are not well absorbed into the blood after either oral or topical administration. Polymyxins bind to cell membranes, purulent exudates and tissue debris. The drugs are eliminated from the kidneys with approximately sixty percent of polymyxin B and ninety percent of colistin excreted unchanged. Polymyxins are considered nephrotoxic and neurotoxic and neuromuscular blockade is seen at higher concentrations. In reality, the potential for nephrotoxicity is minimal when the drugs are utilized properly, especially colistin. Polymyxin B is a potent releaser of histamines and hypersensitivity reactions can occur. Parenteral polymyxins are often characterized by intense pain at the injection site. Divalent cations, unsaturated fatty acids and quaternary ammonium compounds inhibit the activity of polymyxins.
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • Third ESVAC Report
    Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency.
    [Show full text]
  • Non-Penicillin Beta-Lactam Drugs: a CGMP Framework for Preventing Cross- Contamination
    Guidance for Industry Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross- Contamination U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) April 2013 Current Good Manufacturing Practices (CGMPs) Guidance for Industry Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross- Contamination Additional copies are available from: Office of Communications Division of Drug Information, WO51, Room 2201 Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave. Silver Spring, MD 20993-0002 Phone: 301-796-3400; Fax: 301-847-8714 [email protected] http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) April 2013 Current Good Manufacturing Practices (CGMP) Contains Nonbinding Recommendations TABLE OF CONTENTS I. INTRODUCTION....................................................................................................................1 II. BACKGROUND ......................................................................................................................2 III. RECOMMENDATIONS.........................................................................................................7 i Contains Nonbinding Recommendations Guidance for Industry1 Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination This guidance
    [Show full text]
  • A Practical Guide to the Use of the Anatomical Therapeutic Chemical Classification and Defined Daily Dose System Methodology in Canada
    Hutchinson.qxd 2/6/04 3:43 PM Page 29 View metadata, citation and similar papers at core.ac.uk brought to you by CORE SPECIAL ARTICLE provided by Memorial University Research Repository Measurement of antibiotic consumption: A practical guide to the use of the Anatomical Therapeutic Chemical classification and Defined Daily Dose system methodology in Canada James M Hutchinson MD FRCPC1, David M Patrick MD MHSc FRCPC2, Fawziah Marra PharmD2, Helen Ng BSc2, William R Bowie MD FRCPC2, Laurie Heule BSc(Pharm)3, Mark Muscat MD MSc4, Dominique L Monnet PharmD PhD4 JM Hutchinson, DM Patrick, F Marra, et al. Measurement of Mesure de la consommation d’antibiotiques : antibiotic consumption: A practical guide to the use of the guide pratique concernant l’utilisation du Anatomical Therapeutic Chemical classification and Defined Système de classification anatomique thérapeu- Daily Dose system methodology in Canada. Can J Infect Dis tique chimique et du système de posologie quoti- 2004;15(1):29-35. dienne recommandée au Canada Despite the global public health importance of resistance of micro- Malgré l’importance, en santé publique, de la résistance des micro- organisms to the effects of antibiotics, and the direct relationship of organismes aux effets des antibiotiques et le lien direct entre la consumption to resistance, little information is available concerning consommation et cette résistance, il existe peu de données sur le degré de levels of consumption in Canadian hospitals and out-patient settings. consommation des antibiotiques dans les hôpitaux et les services de The present paper provides practical advice on the use of administra- consultations externes au Canada.
    [Show full text]
  • The Effects of Combination Antibiotic Therapy on Methicillin-Resistant Staphylococcus Aureus Presented by Kasra Nick Fallah In
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UT Digital Repository The Effects of Combination Antibiotic Therapy on Methicillin-Resistant Staphylococcus aureus Presented by Kasra Nick Fallah in partial fulfillment of the requirements for completion of the Health Science Scholars honors program in the College of Natural Sciences at The University of Texas at Austin Spring 2018 Gregory C. Palmer, Ph.D. Date Supervising Professor Texas Institute for Discovery Education in Science Department of Medical Education Ruth Buskirk, Ph.D. Date Biology Honors Advisor Biological Sciences, College of Natural Sciences Table of Contents Abstract (3) Chapter 1: Literature Review (4) 1.1: The History of Antibiotics (4) 1.1.1: The Discovery of Penicillin (4) 1.1.2: The Different Classes of Antibiotics (7) 1.1.3: The Mechanisms of Action of Antibiotics (13) 1.2: Antibiotic Resistance (16) 1.2.1: The Rise of Antibiotic Resistance (16) 1.2.2: Mechanisms of Resistance (17) 1.2.3: How Antibiotic Resistance Spreads (20) 1.2.4: Methicillin-Resistant Staphylococcus aureus (21) 1.3: Streptomyces (24) 1.3.1: Selman Waksman (24) 1.3.2: Streptomyces: A Possible Solution to Antibiotic Resistance (25) 1.4: Combination Antibiotic Therapy (27) 1.4.1: The Positive/Negative Effects of Combination Antibiotic Therapy (27) 1.4.2: Drug Interactions (29) 1.4.3: Antibiotic Stewardship (30) Chapter 2: Research Manuscript (32) 2.1: Introduction (32) 1 2.2: Methods (35) 2.2.1: Strains, Media, and Growth Conditions (35) 2.2.2: Bacterial Strain Isolation and Identification (35) 2.2.3: Ethyl acetate Extractions (36) 2.2.4: Disc Assays (36) 2.3: Results & Discussion (38) 2.3.1: Isolation of Bacteria (38) 2.3.2: Organic Extractions (41) 2.3.3: Inhibition of MSSA and MRSA (41) 2.3.4: Inhibitory effect of the antibiotic produced by S.
    [Show full text]
  • Antibiotic Resistance Threats in the United States, 2019
    ANTIBIOTIC RESISTANCE THREATS IN THE UNITED STATES 2019 Revised Dec. 2019 This report is dedicated to the 48,700 families who lose a loved one each year to antibiotic resistance or Clostridioides difficile, and the countless healthcare providers, public health experts, innovators, and others who are fighting back with everything they have. Antibiotic Resistance Threats in the United States, 2019 (2019 AR Threats Report) is a publication of the Antibiotic Resistance Coordination and Strategy Unit within the Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention. Suggested citation: CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. Available online: The full 2019 AR Threats Report, including methods and appendices, is available online at www.cdc.gov/DrugResistance/Biggest-Threats.html. DOI: http://dx.doi.org/10.15620/cdc:82532. ii U.S. Centers for Disease Control and Prevention Contents FOREWORD .............................................................................................................................................V EXECUTIVE SUMMARY ........................................................................................................................ VII SECTION 1: THE THREAT OF ANTIBIOTIC RESISTANCE ....................................................................1 Introduction .................................................................................................................................................................3
    [Show full text]